Complete Biochemical Response After Stereotactic Ablative Radiotherapy of an Isolated Prostate Cancer Pelvic Soft Tissue Recurrence Detected by 18F-DCFPyL PET/CT

Overview

Journal Urol Case Rep

Specialty Urology

Date 2017 Dec 12

PMID 29226093

Citations 3

Authors

Ryan M Phillips

Michael A Gorin

Steven P Rowe

Martin G Pomper

Kenneth J Pienta

Ashley E Ross

Phuoc T Tran

Affiliations

Soon will be listed here.

Citing Articles

Prostate Cancer Theranostics - An Overview.

Abou D, Benabdallah N, Jiang W, Peng L, Zhang H, Villmer A Front Oncol. 2020; 10:884.

PMID: 32582550 PMC: 7290246. DOI: 10.3389/fonc.2020.00884.

Targeted Ultrasound Contrast Imaging of Tumor Vasculature With Positively Charged Microbubbles.

Diakova G, Du Z, Klibanov A Invest Radiol. 2020; 55(11):736-740.

PMID: 32569011 PMC: 10690642. DOI: 10.1097/RLI.0000000000000699.

Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern.

Yin Y, Paller C, Pomper M, Pienta K, Gorin M, Rowe S World J Nucl Med. 2020; 18(4):424-427.

PMID: 31933562 PMC: 6945367. DOI: 10.4103/wjnm.WJNM_50_18.

References

Tosoian J, Gorin M, Ross A, Pienta K, Tran P, Schaeffer E . Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2016; 14(1):15-25. PMC: 5808411. DOI: 10.1038/nrurol.2016.175. View

Rowe S, Mana-Ay M, Javadi M, Szabo Z, Leal J, Pomper M . PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?. Clin Genitourin Cancer. 2015; 14(1):e115-8. PMC: 4698229. DOI: 10.1016/j.clgc.2015.09.011. View

Garcia-Albeniz X, Chan J, Paciorek A, Logan R, Kenfield S, Cooperberg M . Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015; 51(7):817-24. PMC: 4402138. DOI: 10.1016/j.ejca.2015.03.003. View

Rowe S, Macura K, Mena E, Blackford A, Nadal R, Antonarakis E . PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Mol Imaging Biol. 2016; 18(3):411-9. PMC: 5261857. DOI: 10.1007/s11307-016-0957-6. View

Duchesne G, Woo H, Bassett J, Bowe S, DEste C, Frydenberg M . Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016; 17(6):727-737. DOI: 10.1016/S1470-2045(16)00107-8. View